Jessee M. Jaynes - 25 Aug 2023 Form 3 Insider Report for Genvor Inc (GNVR)

Role
Chief Research Officer, Director
Signature
/s/ Dr. Jesse Jaynes
Issuer symbol
GNVR
Transactions as of
25 Aug 2023
Transactions value $
$0
Form type
3
Filing time
05 Dec 2025, 16:06:06 UTC
Next filing
05 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Jaynes Jessee M Chief Research Officer, Director 1550 W HORIZON RIDGE PKWY, STE R #3040, HENDERSON /s/ Dr. Jesse Jaynes 05 Dec 2025 0002075345

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding GNVR Series B Preferred Stock 25 Aug 2023 Common Stock 4.77M Direct F1
holding GNVR Series B Preferred Stock 25 Aug 2023 Common Stock 2M Jaynes Investment LLC F2
holding GNVR Series B Preferred Stock 25 Aug 2023 Common Stock 3 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 As of August 25, 2023, the date that the issuer filed its registration statement on Form 8-A, Dr. Jaynes and his spouse, Mary Jaynes, jointly owned 476,762 shares of Series B Preferred Stock. Each share of Series B Preferred Stock is convertible at the election of the holder into 10 shares of common stock, such that 4,767,620 shares of common stock are issuable upon conversion of the Jaynes' Series B Preferred Stock.
F2 Dr. Jaynes may be deemed to be the beneficial owner of 200,000 shares of the issuer's Series B Preferred Stock, held in the name of Jaynes Investment LLC as of August 25, 2023. Each share of Series B Preferred Stock is convertible at the election of the holder into 10 shares of common stock, such that 2,000,000 shares of common stock are issuable upon conversion of Jaynes Investment LLC's Series B Preferred Stock.
F3 As of August 25, 2023, Dr. Jaynes owns 3 shares of the issuer's Series A Preferred Stock. Each share of Series A Preferred Stock is convertible at the election of the holder into 1 share of common stock, such that 3 shares of common stock are issuable upon conversion of Dr. Jaynes' Series A Preferred Stock.